The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease

A randomized controlled trial

Yoshihiro Sato, Yoshiaki Honda, Kazuo Umeno, Norimasa Hayashida, Jun Iwamoto, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may modifiable by intervention with menatetrenone (vitamin K2) and risedronate sodium; we address the possibility that treatment with menatetrenone, risedronate and calcium may reduce the incidence of nonvertebral fractures in elderly patients with AD. A total of 231 elderly patients with AD were randomly assigned to daily treatment with 45 mg of menatetrenone or a placebo combined with once weekly risedronate sodium, and followed up for 12 months. At baseline, patients of both groups showed high undercarboxylated osteocalcin (ucOC) and low 25-OHD insufficiency with compensatory hyperparathyroidism. During the study period, BMD in the treatment group increased by 5.7% and increased by 2.1% in the control group. Nonvertebral fractures occurred in 15 patients (10 hip fractures) in the control group and 5 patients (2 hip fractures) in the treatment group. The relative risk in the treatment group compared with the control group was 0.31 (95% confidence interval, 0.12-0.81). Elderly AD patients with hypovitaminosis K and D are at increased risk for hip fracture. The study medications were well tolerated with relatively few adverse events and effective in reducing the risk of a fracture in elderly patients with AD.

Original languageEnglish
Pages (from-to)117-124
Number of pages8
JournalKurume Medical Journal
Volume57
Issue number4
DOIs
Publication statusPublished - 2010

Fingerprint

Hip Fractures
Alzheimer Disease
Randomized Controlled Trials
Calcium
Hyperparathyroidism
Bone Density
Control Groups
Vitamin K Deficiency
Therapeutics
menatetrenone
Risedronate Sodium
Vitamin K 2
Osteocalcin
Incidence
Osteoporosis
Placebos
Confidence Intervals

Keywords

  • Alzheimer disease
  • Fall
  • Hip fracture
  • Osteoporosis
  • Vitamin K deficiency

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease : A randomized controlled trial. / Sato, Yoshihiro; Honda, Yoshiaki; Umeno, Kazuo; Hayashida, Norimasa; Iwamoto, Jun; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Kurume Medical Journal, Vol. 57, No. 4, 2010, p. 117-124.

Research output: Contribution to journalArticle

Sato, Yoshihiro ; Honda, Yoshiaki ; Umeno, Kazuo ; Hayashida, Norimasa ; Iwamoto, Jun ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease : A randomized controlled trial. In: Kurume Medical Journal. 2010 ; Vol. 57, No. 4. pp. 117-124.
@article{0e0e84f2d9584ad293b5f205ebe82368,
title = "The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: A randomized controlled trial",
abstract = "A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may modifiable by intervention with menatetrenone (vitamin K2) and risedronate sodium; we address the possibility that treatment with menatetrenone, risedronate and calcium may reduce the incidence of nonvertebral fractures in elderly patients with AD. A total of 231 elderly patients with AD were randomly assigned to daily treatment with 45 mg of menatetrenone or a placebo combined with once weekly risedronate sodium, and followed up for 12 months. At baseline, patients of both groups showed high undercarboxylated osteocalcin (ucOC) and low 25-OHD insufficiency with compensatory hyperparathyroidism. During the study period, BMD in the treatment group increased by 5.7{\%} and increased by 2.1{\%} in the control group. Nonvertebral fractures occurred in 15 patients (10 hip fractures) in the control group and 5 patients (2 hip fractures) in the treatment group. The relative risk in the treatment group compared with the control group was 0.31 (95{\%} confidence interval, 0.12-0.81). Elderly AD patients with hypovitaminosis K and D are at increased risk for hip fracture. The study medications were well tolerated with relatively few adverse events and effective in reducing the risk of a fracture in elderly patients with AD.",
keywords = "Alzheimer disease, Fall, Hip fracture, Osteoporosis, Vitamin K deficiency",
author = "Yoshihiro Sato and Yoshiaki Honda and Kazuo Umeno and Norimasa Hayashida and Jun Iwamoto and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2010",
doi = "10.2739/kurumemedj.57.117",
language = "English",
volume = "57",
pages = "117--124",
journal = "Kurume Medical Journal",
issn = "0023-5679",
publisher = "Kurume University School of Medicine",
number = "4",

}

TY - JOUR

T1 - The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease

T2 - A randomized controlled trial

AU - Sato, Yoshihiro

AU - Honda, Yoshiaki

AU - Umeno, Kazuo

AU - Hayashida, Norimasa

AU - Iwamoto, Jun

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2010

Y1 - 2010

N2 - A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may modifiable by intervention with menatetrenone (vitamin K2) and risedronate sodium; we address the possibility that treatment with menatetrenone, risedronate and calcium may reduce the incidence of nonvertebral fractures in elderly patients with AD. A total of 231 elderly patients with AD were randomly assigned to daily treatment with 45 mg of menatetrenone or a placebo combined with once weekly risedronate sodium, and followed up for 12 months. At baseline, patients of both groups showed high undercarboxylated osteocalcin (ucOC) and low 25-OHD insufficiency with compensatory hyperparathyroidism. During the study period, BMD in the treatment group increased by 5.7% and increased by 2.1% in the control group. Nonvertebral fractures occurred in 15 patients (10 hip fractures) in the control group and 5 patients (2 hip fractures) in the treatment group. The relative risk in the treatment group compared with the control group was 0.31 (95% confidence interval, 0.12-0.81). Elderly AD patients with hypovitaminosis K and D are at increased risk for hip fracture. The study medications were well tolerated with relatively few adverse events and effective in reducing the risk of a fracture in elderly patients with AD.

AB - A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may modifiable by intervention with menatetrenone (vitamin K2) and risedronate sodium; we address the possibility that treatment with menatetrenone, risedronate and calcium may reduce the incidence of nonvertebral fractures in elderly patients with AD. A total of 231 elderly patients with AD were randomly assigned to daily treatment with 45 mg of menatetrenone or a placebo combined with once weekly risedronate sodium, and followed up for 12 months. At baseline, patients of both groups showed high undercarboxylated osteocalcin (ucOC) and low 25-OHD insufficiency with compensatory hyperparathyroidism. During the study period, BMD in the treatment group increased by 5.7% and increased by 2.1% in the control group. Nonvertebral fractures occurred in 15 patients (10 hip fractures) in the control group and 5 patients (2 hip fractures) in the treatment group. The relative risk in the treatment group compared with the control group was 0.31 (95% confidence interval, 0.12-0.81). Elderly AD patients with hypovitaminosis K and D are at increased risk for hip fracture. The study medications were well tolerated with relatively few adverse events and effective in reducing the risk of a fracture in elderly patients with AD.

KW - Alzheimer disease

KW - Fall

KW - Hip fracture

KW - Osteoporosis

KW - Vitamin K deficiency

UR - http://www.scopus.com/inward/record.url?scp=79961002299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961002299&partnerID=8YFLogxK

U2 - 10.2739/kurumemedj.57.117

DO - 10.2739/kurumemedj.57.117

M3 - Article

VL - 57

SP - 117

EP - 124

JO - Kurume Medical Journal

JF - Kurume Medical Journal

SN - 0023-5679

IS - 4

ER -